Luca Gianaroli, Amerigo Vitagliano, Anna P Ferraretti, Silvia Azzena, Gaia Terzuoli, Davide Perruzza, Guido Ambrosini, Carla Tabanelli, M Cristina Magli
Reproductive biomedicine online 2022 AugThe IVF Lite programme is based on mild ovarian stimulation including up to three fresh/frozen embryo transfers within 12 months. Is it effective and safe in good prognosis patients? Single-centre prospective study on infertile patients at their first IVF attempt (female age ≤38 years, anti-Müllerian hormone concentrations >1.5 ng/ml and/or FSH ≤10 mIU/ml). Induction of multiple follicular growth was based on a fixed protocol consisting of clomiphene citrate (100 mg/day) from day 3 to 7 of the menstrual cycle and 150 IU of recombinant FSH on days 5, 7 and 9. In case of low follicular recruitment (fewer than four follicles), the cycle was cancelled. The IVF Lite programme was considered complete after a live birth delivery or up to three embryo transfers within 12 months. The primary outcome was the cumulative live birth rate (cLBR) per couples that completed the programme. A total of 369 patients completed the IVF Lite programme, with 239 live births; 132 patients delivered after one embryo transfer (35.8%), 70 after a second embryo transfer (cLBR 54.7%), and 37 after a third attempt (cLBR 64.8%). No cases of ovarian hyperstimulation syndrome or clinical complications occurred. Spontaneous dropout rate from the programme was 4.5%. The cLBR per intention to treat was 46.8%. The IVF Lite programme proved to be effective and safe in good prognosis patients with a good response to clomiphene citrate stimulation. It was well tolerated and implied low gonadotrophin consumption. Two-thirds of the patients achieved a live birth at the completion of the programme. Copyright © 2022. Published by Elsevier Ltd.
Luca Gianaroli, Amerigo Vitagliano, Anna P Ferraretti, Silvia Azzena, Gaia Terzuoli, Davide Perruzza, Guido Ambrosini, Carla Tabanelli, M Cristina Magli. IVF Lite: a smart IVF programme based on mild ovarian stimulation for good prognosis patients. Reproductive biomedicine online. 2022 Aug;45(2):256-263
PMID: 35610154
View Full Text